Key references: Pharmacological treatment for insomnia in adults

Prescribing drugs of dependence in general practice: Part B - benzodiazepines. Melbourne: Royal Australian College of General Practitioners (RACGP); 2015. https://www.racgp.org.au/clinical-resources/clinical-guidelines/key-racgp-guidelines/view-all-racgp-guidelines/drugs-of-dependence/part-b
Baldwin DS, Aitchison K, Bateson A, Curran HV, Davies S, Leonard B, et al. Benzodiazepines: risks and benefits. A reconsideration. J Psychopharmacol 2013;27(11):967–71. https://www.ncbi.nlm.nih.gov/pubmed/24067791
Brett J. Concerns about quetiapine. Aust Prescr 2015;38(3):95–7. https://www.ncbi.nlm.nih.gov/pubmed/26648630
Byard RW, Musgrave I, Maker G, Bunce M. What risks do herbal products pose to the Australian community? Med J Aust 2017;206(2):86–90. https://www.ncbi.nlm.nih.gov/pubmed/28152355
Citrome L. Suvorexant for insomnia: a systematic review of the efficacy and safety profile for this newly approved hypnotic - what is the number needed to treat, number needed to harm and likelihood to be helped or harmed? Int J Clin Pract 2014;68(12):1429–41. https://www.ncbi.nlm.nih.gov/pubmed/25231363
Clay E, Falissard B, Moore N, Toumi M. Contribution of prolonged-release melatonin and anti-benzodiazepine campaigns to the reduction of benzodiazepine and Z-drugs consumption in nine European countries. Eur J Clin Pharmacol 2013;69(4):1–10. https://www.ncbi.nlm.nih.gov/pubmed/23114457
Cunnington D, Junge M. Chronic insomnia: diagnosis and non-pharmacological management. BMJ 2016;355:i5819. https://www.ncbi.nlm.nih.gov/pubmed/27852564
Cunnington D, Junge MF, Fernando AT. Insomnia: prevalence, consequences and effective treatment. Med J Aust 2013;199(8):S36–40. https://www.ncbi.nlm.nih.gov/pubmed/24138364
Erland LA, Saxena PK. Melatonin natural health products and supplements: presence of serotonin and significant variability of melatonin content. J Clin Sleep Med 2017;13(2):275–81. https://www.ncbi.nlm.nih.gov/pubmed/27855744
Everitt H, Baldwin DS, Stuart B, Lipinska G, Mayers A, Malizia AL, et al. Antidepressants for insomnia in adults. Cochrane Database Syst Rev 2018;5:CD010753. https://www.ncbi.nlm.nih.gov/pubmed/29761479
Grigg-Damberger MM, Ianakieva D. Poor quality control of over-the-counter melatonin: What they say is often not what you get. J Clin Sleep Med 2017;13(2):163–5. https://www.ncbi.nlm.nih.gov/pubmed/28095978
Gunja N. In the Zzz zone: the effects of Z-drugs on human performance and driving. J Med Toxicol 2013;9(2):163–71. https://www.ncbi.nlm.nih.gov/pubmed/23456542
Huedo-Medina TB, Kirsch I, Middlemass J, Klonizakis M, Siriwardena AN. Effectiveness of non-benzodiazepine hypnotics in treatment of adult insomnia: meta-analysis of data submitted to the Food and Drug Administration. BMJ 2012;345:e8343. https://www.ncbi.nlm.nih.gov/pubmed/23248080
Keks NA, Hope J, Keogh S. Suvorexant: scientifically interesting, utility uncertain. Australas Psychiatry 2017;25(6):622–4. https://www.ncbi.nlm.nih.gov/pubmed/28994603
Kishi T, Matsunaga S, Iwata N. Suvorexant for primary insomnia: a systematic review and meta-analysis of randomized placebo-controlled trials. PLoS One 2015;10(8):e0136910. https://www.ncbi.nlm.nih.gov/pubmed/26317363
Kuriyama A, Tabata H. Suvorexant for the treatment of primary insomnia: A systematic review and meta-analysis. Sleep Med Rev 2017;35:1–7. https://www.ncbi.nlm.nih.gov/pubmed/28365447
Morin CM, Edinger JD, Beaulieu-Bonneau S, Ivers H, Krystal AD, Guay B, et al. Effectiveness of sequential psychological and medication therapies for insomnia disorder: a randomized clinical trial. JAMA Psychiatry 2020. https://www.ncbi.nlm.nih.gov/pubmed/32639561
National Institute for Health and Care Excellence (NICE). Hypnotics: key therapeutic topic [KTT6]. London: NICE; 2015 (updated 2019). https://www.nice.org.uk/advice/ktt6
Qaseem A, Kansagara D, Forciea MA, Cooke M, Denberg TD, Clinical Guidelines Committee of the American College of P. Management of chronic insomnia disorder in adults: a clinical practice guideline from the American College of Physicians. Ann Intern Med 2016;165(2):125–33. https://www.ncbi.nlm.nih.gov/pubmed/27136449
Riemann D, Baglioni C, Bassetti C, Bjorvatn B, Dolenc Groselj L, Ellis JG, et al. European guideline for the diagnosis and treatment of insomnia. J Sleep Res 2017;26(6):675–700. https://www.ncbi.nlm.nih.gov/pubmed/28875581
Sateia MJ, Buysse DJ, Krystal AD, Neubauer DN, Heald JL. Clinical practice guideline for the pharmacologic treatment of chronic insomnia in adults: An American Academy of Sleep Medicine clinical practice guideline. J Clin Sleep Med 2017;13(2):307–49. https://www.ncbi.nlm.nih.gov/pubmed/27998379
Thompson W, Quay TAW, Rojas-Fernandez C, Farrell B, Bjerre LM. Atypical antipsychotics for insomnia: a systematic review. Sleep Med 2016;22:13–7. https://www.ncbi.nlm.nih.gov/pubmed/27544830
Wilson S, Anderson K, Baldwin D, Dijk DJ, Espie A, Espie C, et al. British Association for Psychopharmacology consensus statement on evidence-based treatment of insomnia, parasomnias and circadian rhythm disorders: An update. J Psychopharmacol 2019;33(8):923–47. https://www.ncbi.nlm.nih.gov/pubmed/31271339
Wilt TJ, MacDonald R, Brasure M, Olson CM, Carlyle M, Fuchs E, et al. Pharmacologic treatment of insomnia disorder: an evidence report for a clinical practice guideline by the American College of Physicians. Ann Intern Med 2016;165(2):103–12. https://www.ncbi.nlm.nih.gov/pubmed/27136278